Latest / Cardiac Consult: A Cleveland Clinic Podcast for Healthcare Professionals
CTX310 and the Future of Gene Editing for Lipid Disorders
Steven Nissen, MD, and Luke Laffin, MD, discuss one-year follow-up data for CTX310, a CRISPR-Cas9 gene-editing therapy targeting ANGPTL3 to treat lipid disorders. They review the sustained reductions in LDL cholesterol and triglycerides, and the potential role of one-time gene-editing therapies in cardiovascular prevention and lipid management.
Read the article. https://consultqd.clevelandclinic.org/effects-of-crispr-cas9-gene-editing-for-dyslipidemia-endure-1-year
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.